Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Anika Therapeutics, Inc. Director's Dealing 2012

Mar 8, 2012

33997_dirs_2012-03-08_ac09f969-bdbd-480d-afcf-2ac71480c0b1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANIKA THERAPEUTICS INC (ANIK)
CIK: 0000898437
Period of Report: 2012-03-01

Reporting Person: LUPPINO FRANCESCO J (Chief Operating Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2012-03-01 Stock Option (Right to Buy) $6.99 A 37500 Acquired 2022-03-01 Common Stock (37500) Direct

Footnotes

F1: The exercise price of the stock options represents the closing price of the Company's common stock on June 7, 2011, the date the Board of Directors of the Company granted performance-based stock option awards (the "Performance Grant") and approved the performance measures governing such Performance Grant.

F2: The stock options were issued under the Performance Grant on March 1, 2012, the date the Compensation Committee of the Company determined that certain performance measures governing the Performance Grant were achieved.

F3: The stock options vest in three equal installments as follows: March 1, 2012, January 1, 2013, and January 1, 2014